“Those of us who work with NK cells have no doubt that they are incredibly powerful at killing cancer cells,” said Veronika Bachanova, MD, PhD.
News|Videos|December 19, 2017
Updates in Splenic and Nodal Marginal Zone Lymphoma
Author(s)Catherine Thieblemont, MD, PhD
This video reviews updates on the treatment and biology of splenic and nodal marginal zone lymphoma.
Advertisement
In this video, Catherine Thieblemont, MD, PhD, of Hopital Saint-Louis in Paris, discusses updates on the treatment and biology of splenic and nodal marginal zone lymphoma.
Thieblemont gave a presentation on this topic during an education session at the 2017 American Society of Hematology (ASH) Annual Meeting and Exposition, held December 9–12 in Atlanta.
Advertisement
Related to this article
The approval expands the indication of pirtobrutinib to patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma with no known 17p deletion.
The FDA has assigned a Prescription Drug User Fee Act date of March 31, 2027, for tabelecleucel in this indication.
An expert panel discusses the case for de-escalating antibiotic therapy for pediatric patients who undergo hematopoietic cell transplantation.
“No one should be excluded from any clinical trial,” said Paul G. Rubinstein, MD, regarding patients with HIV-associated cancers in cooperative group studies.
Veronika Bachanova, MD, PhD, discussed how the favorable safety profile of CAR natural killer cell therapies may come with trade-offs in persistence and response durability.
Adding fixed-duration epcoritamab to R-CHOP reduced the risk of progression or death by 51% in patients with newly diagnosed DLBCL.
Paul Rubinstein, MD, discussed how cooperative groups are expanding CAR T and bispecific antibody research for patients with HIV-associated lymphoma.
Advertisement
Advertisement
Trending on CancerNetwork
1
VS-7375 Yields Responses in KRAS G12D–Mutated Solid Tumors
2
Reading a Changed Eye Examination and Impact on Therapy
3
Operationalizing the First Dose and Building the Oncology and Eye Care Partnership
4
FDA Expands Approval for Nogapendekin Alfa in BCG-Unresponsive NMIBC
5